{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:13Z","timestamp":1761897373727,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.advms.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:49:09Z","timestamp":1599698949000},"page":"429-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group"],"prefix":"10.1016","volume":"65","author":[{"given":"Aleksandra","family":"Go\u0142os","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Boguradzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Ha\u0142aburda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Sobczyk-Kruszelnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Dybko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"D\u0119bek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Warzocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.advms.2020.08.003_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.advms.2020.08.003_bib2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.advms.2020.08.003_bib3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.advms.2020.08.003_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","article-title":"Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation","volume":"121","author":"Perez-Simon","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.advms.2020.08.003_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.advms.2020.08.003_bib6","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.advms.2020.08.003_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kroger","year":"2009","journal-title":"Exp Hematol"},{"issue":"13","key":"10.1016\/j.advms.2020.08.003_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.advms.2020.08.003_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.advms.2020.08.003_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clml.2015.03.016","article-title":"Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic","volume":"15","author":"Mir","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"10.1016\/j.advms.2020.08.003_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.bbmt.2013.03.012","article-title":"Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry","volume":"19","author":"Passera","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.advms.2020.08.003_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.advms.2020.08.003_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bmt.2009.14","article-title":"Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect","volume":"44","author":"Khaled","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.advms.2020.08.003_bib14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.advms.2020.08.003_bib15","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.advms.2020.08.003_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.advms.2020.08.003_bib17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American society for blood and marrow transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.advms.2020.08.003_bib18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.advms.2020.08.003_bib19","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.advms.2020.08.003_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12185-015-1873-2","article-title":"Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"102","author":"Kikuchi","year":"2015","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.advms.2020.08.003_bib21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.leu.2404333","article-title":"The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"20","author":"Bensinger","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.advms.2020.08.003_bib22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bmt.2015.45","article-title":"Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma","volume":"50","author":"Sahebi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.advms.2020.08.003_bib23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.advms.2020.08.003_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bmt.2014.320","article-title":"Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution","volume":"50","author":"Rosi\u00f1ol","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.advms.2020.08.003_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2016.03.001","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: impact of disease risk and post allograft minimal residual disease on survival","volume":"16","author":"Dhakal","year":"2016","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1016\/j.advms.2020.08.003_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbmt.2017.09.017","article-title":"Impact of new drugs on the long-term follow-up of upfront tandem autograft-allograft in multiple myeloma","volume":"24","author":"Giaccone","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.advms.2020.08.003_bib27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.advms.2020.08.003_bib28","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.advms.2020.08.003_bib29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41409-020-0887-4","article-title":"Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation","volume":"55","author":"Costa","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.advms.2020.08.003_bib30","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.advms.2020.08.003_bib31","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.advms.2020.08.003_bib32","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.advms.2020.08.003_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","article-title":"Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials Network 0102 trial","volume":"26","author":"Giralt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.advms.2020.08.003_bib34","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.advms.2020.08.003_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2015.319","article-title":"Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation","volume":"51","author":"Ahmad","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.advms.2020.08.003_bib36","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:42:36Z","timestamp":1761824556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112620300353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1896112620300353"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2020.08.003","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}